National Comprehensive Cancer Network Receives $1.5 Million Grant to Research Targeted Therapy in Bladder Cancer

FORT WASHINGTON, Pa.--(BUSINESS WIRE)--The National Comprehensive Cancer Network (NCCN), Bristol-Myers Squibb Company and ImClone Systems Incorporated have entered into a collaboration to conduct a multi-institutional, investigator-initiated study in bladder cancer using cetuximab (ERBITUX®, Bristol-Myers Squibb Company/ImClone Systems Incorporated). The University of Michigan Comprehensive Cancer Center is the coordinating center for the study supported by a $1.5 Million grant.